Kyverna Therapeutics

IPO

Kyverna Therapeutics is a healthcare company in Emeryville, United States, founded in 2018. It has raised $110.0M across 3 rounds, most recently an $85.0M Series B in August 2023.

Kyverna is Developing Cell Therapies for Autoimmune Diseases

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$110.0M
Last Round
$85.0M Series BAug 2023
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 2 investors for this company. The full record is or through the API.

About

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies designed to achieve treatment-free remission in autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (KYV-101), is in Phase 2 trials across lupus nephritis, multiple sclerosis, myasthenia gravis, and stiff-person syndrome. Kyverna went public on Nasdaq in February 2024.

Summary

It lists 51–200 employees. It has raised $110.0M in total across 3 rounds, most recently a $85.0M Series B round in Aug 2023. Investors include Gilead Sciences and Vida Ventures.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
Debt FinancingDebt FinancingNov 2025
$150.0M

Sign up to see all 5 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
PHC

PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...

Minato, Japan5001–10000Healthcare, Life Sciences
Private EquityTotal funding$1.9BMar 2021
Oscar HealthIPO

Oscar Health uses technology to deliver simple, personalized health insurance and member-care exp...

New York, United States1001–5000Healthcare, Insurance
ConvertibleTotal funding$1.8BOct 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Kyverna Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/kyverna-therapeutics"><img src="https://indexed.vc/api/badge/company/kyverna-therapeutics" alt="Kyverna Therapeutics on Indexed.vc" width="260" height="76" /></a>